Technology
Instem plc
Analysts
Quick links:
Company Description
Instem is a leading provider of IT solutions & services to the life sciences market. Instem provides advanced IT solutions to the global health and life sciences community which improves the productivity of their processes in the discovery and development of new drugs, therapies and products.
Investment Summary
Instem came to market in 2010 with a compelling story based on dominance of a niche market, good recurring revenues and strong cash generation. In our view, the group has a strong track record of delivery, and the favourable market backdrop gives further confidence in the growth story.
Recent Content
Impressive growth in FY22
31/01/2023 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2022, reporting c.28% revenue growth […]
Major license fee underpins full-year result
22/12/2022 Instem plc
Instem has announced a major contract extension with an existing customer for its Provantis study management software. The […]
Another positive period for Instem
27/09/2022 Instem plc
Instem has once again delivered a strong set of interim results, in our view, with the outcome consistent […]
Largest ever contract validates growth strategy
05/09/2022 Instem plc
Instem has signed its largest ever single contract, a five-year $12m deal with a leading global contract research […]
H1 22 – strong trading and positive outlook
04/08/2022 Instem plc
Instem’s update for the six months to 30 June 2022 (H1 22) confirms that the business continues to […]
FY21 Strong financial performance, strategic transformation
26/04/2022 Instem plc
Instem has reported FY21 results consistent with the January trading statement and in line with our forecasts. Despite […]
Bringing drugs to market faster
25/02/2022 Instem plc
Instem offers an opportunity to invest in a business with two specific attractions – (1) The group is […]
Trading in-line, all key metrics improving
26/01/2022 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2021, reporting like-for-like (LFL) revenue […]
Strong organic and acquisitive growth
29/09/2021 Instem plc
Instem has once again delivered a strong set of interim results in our view, with the growth story […]
A strategic move in Switzerland
01/09/2021 Instem plc
Instem has announced the (earnings enhancing) acquisition of PDS Pathology Data Systems Ltd (“PDS”) a Swiss-based life sciences […]
H1 21 trading: strength across the board
19/07/2021 Instem plc
Instem’s update for the six months to 30 June 2021 (H1 21E) confirms that trading was in line […]
FY 20A: Solid growth, despite COVID-19
12/04/2021 Instem plc
Instem has reported FY 20A results consistent with its Jan-21 trading statement and in line with our forecasts. […]
Transformational deal in clinical trial analysis
22/03/2021 Instem plc
Instem has announced that it has exchanged contracts to acquire d-Wise Technologies Inc (“d-wise”) a US-based clinical trial […]
Strengthening the position in Discovery
01/03/2021 Instem plc
Instem has announced the (earnings enhancing) acquisition of UK-based Discovery software solutions provider The Edge Software Consultancy Ltd […]
Strong end to 2020 – positioned for growth
14/01/2021 Instem plc
Instem has delivered a positive trading update for the year to 31 December 2020 – revenue growth was […]
Momentum remains strong
28/09/2020 Instem plc
Instem has delivered strong H1 20A results in our view. Despite the backdrop of COVID-19, all three business […]
Strong trading, successful fundraise
20/07/2020 Instem plc
Instem’s H1 20E trading update confirms that trading was in line with the Board’s expectations during the period. […]
Solid trading, strong delivery
03/06/2020 Instem plc
Instem has reported FY 19A results consistent with the March-20 trading statement and in line with our forecasts. […]
Defensive in uncertain times
25/03/2020 Instem plc
Instem has released a trading update in lieu of FY 19 results scheduled for March 30. The announcement […]
Firing on all cylinders
13/01/2020 Instem plc
Instem’s trading update for the twelve months ending December 2019 confirms that all three key business areas (Data […]
Acquisition in safety assessment
18/11/2019 Instem plc
Instem has announced the acquisition, for up to $4.6m, of a US-based provider of software for safety assessments. […]
Informatics in focus
16/10/2019 Instem plc
We recently met with the divisional management of one of Instem’s businesses – Informatics. Despite its relatively small […]
Building momentum
23/09/2019 Instem plc
Instem has announced solid H1 2019A results in our view. All three business areas performed well during the […]
SEND, SaaS and strength of pipeline
15/07/2019 Instem plc
Instem has published a trading update for H1 2019E – the group is trading well, and we make […]
Another year of solid delivery
01/04/2019 Instem plc
Instem has announced FY 18 results in line with our forecasts. The group has made strong commercial progress […]
All business areas performing well
22/01/2019 Instem plc
Instem’s trading update for the twelve months ending December 2018 confirms that all three key business areas (Data […]
Strong margins and cash performance
24/09/2018 Instem plc
Instem has reported interim results consistent with the July trading statement. Revenue grew to £10.5m, with outsourced services […]
FY 18E has started well, SEND accelerating
23/07/2018 Instem plc
Instem’s trading update for the six months ending June 2018 reveals that FY 18E has started well and […]
SEND motoring ahead
26/03/2018 Instem plc
Instem has announced 2017 results in line with our forecasts and consistent with the January trading update. SEND […]
Cloud platform delivering
08/03/2018 Instem plc
Instem has announced that an existing client – one of the world’s largest chemical companies – has adopted […]
A decade in perspective
22/01/2018 Instem plc
The past five years have seen a gradual but dramatic transformation of Instem’s position, and an expansion of […]
Strong end to 2017 & great start 2018
16/01/2018 Instem plc
Instem this morning released an in-line trading statement for the 2017 year. The group is seeing traction across […]
Strategic progress; strong underlying trading
26/09/2017 Instem plc
Instem reported double-digit revenue growth in the first half of 2017, although profitability was reduced by ongoing investment […]
FY 16A results: Solid performance ex-clinical
13/04/2017 Instem plc
Instem’s FY 16A results were line with the Jan-17 trading update and our forecasts. Excluding the Clinical business, […]
2016 Outturn as expected; send on track
16/01/2017 Instem plc
Instem has published a short trading update for the year to December 2016. The outcome was in line […]
Clinical slowdown offsets strength elsewhere
20/12/2016 Instem plc
Instem recently confirmed that its Instem Clinical business continues to be impacted by a slowdown in the early-phase […]
Solid interims
19/09/2016 Instem plc
Instem has announced solid interim results. Revenues grew by 21% YoY, accompanied by a 34% improvement in EBITDA. […]
Strategic step in safety
08/09/2016 Instem plc
Instem, a leading provider of software and services to the earlystage drug development healthcare market, has announced the […]
Samarind acquisition
02/06/2016 Instem plc
Instem has acquired a small software business, Samarind, which is active in the market for Regulatory Information Management […]
A day to remember
25/04/2016 Instem plc
On Friday, Instem held an analyst and investor event at its UK headquarters in Stone. The presentation was […]
Strong FY15 results
05/04/2016 Instem plc
Instem has delivered a strong set of FY15 results. Revenues grew by 22% YoY, accompanied by a 43% […]
Material fundraising to drive growth
03/02/2016 Instem plc
Instem has announced a proposed £5m fundraising via the placing of 2.5m new shares. Monies raised will accelerate […]
Clinical delivery
08/12/2015 Instem plc
Instem has accelerated its payment of the Logos Technologies earnout, in a move that suggests performance in both […]
Strong interims, confident outlook
29/09/2015 Instem plc
Instem has delivered a strong set of interim results. Revenues grew by 31% YoY, with EBITDA showing a […]
Send for the cavalry
19/03/2015 Instem plc
Instem stands to benefit from a December 2014 FDA mandate requiring pre-clinical study submissions to comply with SEND […]
Momentum beginning to build?
12/01/2015 Instem plc
Instem has this morning provided an update on trading for the year to December 2014 – the result […]
The FDA finally presses send
19/12/2014 Instem plc
The US FDA yesterday published “final guidance” around the implementation of a new pre-clinical drug trial data standard, […]
Short-term headwinds; long-term potential
30/09/2014 Instem plc
Instem delivered H1 results showing modest revenue growth (driven by acquisitions) but still leaving a significant step-up required […]
Foundations looking solid; extensions under way
26/03/2014 Instem plc
Instem has reported FY13 results that were modestly ahead of our expectations with revenues around £0.4m (3%) better […]
SAAS contract win
21/02/2014 Instem plc
Instem has announced a useful SaaS contract, which will see the group deliver a third-party software product into […]
Opportunities abound
30/01/2014 Instem plc
Instem sells software products to a variety of customer types involved in the early drug development segment of […]
Company Management Team
Phil Reason
Chief Executive Officer
Phil has been leading Instem as CEO since 1995, working closely with the Instem Board, investors, management, clients, partners and staff to grow the business from a single product line with fifteen clients to serving hundreds of customers as the global market leader across a wide area of life sciences R&D. Passionate about Instem’s ability to support clients in introducing transformational approaches for life changing therapies, Phil has been a vocal advocate of long-term partnerships, innovative organic growth, geographic expansion and the acquisitive consolidation of the fragmented IT supplier community. Under Phil’s leadership Instem has completed the strategic acquisition of 7 companies, has opened new offices in the US, UK, China, and India and has completed a UK-based IPO in 2010.
Nigel Goldsmith
Chief Financial Officer
Nigel joined Instem in November of 2011 and possesses a wealth of experience in senior financial roles at both public and private companies within the life sciences industry. Prior to Instem, Nigel was Finance Director for 3 years at the AIM listed, pharmaceutical and medical devices company, IS Pharma plc. He also held the position of CFO for 7 years at Almedica International Inc., a privately held supplier of clinical trial materials to the global pharmaceutical and biotech markets and 2 years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International plc. Prior to entering industry, Nigel spent over 9 years at KPMG and is a qualified Chartered Accountant.
